Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.01
+0.10 (1.12%)
At close: Oct 2, 2026, 4:00 PM EDT
8.96
-0.05 (-0.55%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $18.69M in the quarter ending June 30, 2026, with 131.22% growth. This brings the company's revenue in the last twelve months to $64.09M, up 327.25% year-over-year. In the year 2025, Xilio Therapeutics had annual revenue of $43.77M with 589.88% growth.
Revenue (ttm)
$64.09M
Revenue Growth
+327.25%
P/S Ratio
0.93
Revenue / Employee
$843,316
Employees
76
Market Cap
59.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 43.77M | 37.42M | 589.88% |
| Dec 31, 2024 | 6.34M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MindWalk Holdings | 11.57M |
| Connect Biopharma Holdings | 2.95M |
| Alterity Therapeutics | 2.50M |
| Hyperion DeFi | 1.40M |
| Mereo BioPharma Group | 500.00K |
| Clene | 197.00K |
XLO News
- 8 hours ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Xilio Therapeutics appoints Houvras as chief medical officer - TheFly
- 4 days ago - Xilio Therapeutics Appoints Yariv J. Houvras, M.D. - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Xilio Therapeutics Quarterly report: Q2 2026 - Filings
- 3 months ago - Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - TheFly